37,584 Results

Data from RELEASE-1 and RELEASE-2 phase III studies of collagenase clostridium histolyticum presented by Endo Pharma at The Aesthetic Society meeting.

 Added 1 day ago

Endo International plc announced that clinical data from a Phase III investigational study of collagenase clostridium histolyticum (CCH) for the...

Updated data on PLEDGE program of relamorelin to treat diabetic gastroparesis.- Allergan

 Added 1 day ago

Allergan plc announced the expansion of the PLEDGE program with a fifth study now evaluating relamorelin, an investigational, ghrelin agonist...

New data for larotrectinib to treat children with TRK fusion cancer. - Bayer

 Added 1 day ago

Bayer has announced findings from new analyses for larotrectinib, showing an overall response rate (ORR) of 94% in children with...

First patient enrolled in phase III clinical trial of fostamatinib to treat warm antibody autoimmune hemolytic anemia .- Rigel Pharma

 Added 2 days ago

Rigel Pharmaceuticals, Inc. announced that it has enrolled the first patient in a pivotal Phase III clinical trial of fostamatinib...

FDA advisory committee does not recommend approval for AC 220 in acute myeloid leukemia.- Daiichi Sankyo

 Added 2 days ago

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 8 to 3 against approving an NDA for AC 220 (quizartinib), from...

European Commission approves triplet therapy (pomalidomide + bortezomib + dexamethasone) for multiple myeloma.- Celgene Corporation

 Added 2 days ago

Celgene Corporation announced that the European Commission (EC) has approved two new triplet regimens based on Celgene’s proprietary IMiD treatments,...

European Commision approval for Revlimid + bortezomib + dexamethasone indicated for the treatment of patients with previously untreated multiple myeloma . Celgene Corporation

 Added 2 days ago

Celgene Corporation announced that the European Commission (EC) has approved two new triplet regimens based on Celgene’s proprietary IMiD treatments,...

ENDO 2020

Cushing's Syndrome

ENDO 2020

The ENDO 2020 annual congress will be held in San Francisco, California on March 28 - 31, 2019.

Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases.

Psoriasis is a chronic skin disease caused by the excessive secretion of inflammatory cytokines. Available therapeutic options include biologic drugs such as tumor necrosis factor alpha inhibitors and interleukin 12/23 (IL-12/23) inhibitors.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Objectives: To compare the efficacy and safety of conventional systemic agents (acitretin, ciclosporin, fumaric acid esters, methotrexate), small molecules (apremilast, tofacitinib, ponesimod), anti‐TNF alpha (etanercept,...

Load more